newsfilter
← Latest News
Business Wire·

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38%